AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

PYC THERAPEUTICS LTD

1.240

+0.0655.53%

Volume:513.07K

Turnover:615.05K

Market Cap:723.24M

PE:-11.26

High:1.240

Open:1.200

Low:1.170

Close:1.175

Loading ...

Overview Company News Filings

BUZZ-Australia's PYC Therapeutics climbs to 1-month high on approval for human trials

PYC Therapeutics Gets Regulatory Approval to Start Human Trials for Polycystic Kidney Disease Drug Candidate; Shares Up 3%

MT Newswires Live

PYC Therapeutics' (ASX:PYC) investors will be pleased with their splendid 107% return over the last five years

Simply Wall St.

ASX Market Update: Real Estate & mining stocks lead index to another all-time high | January 31, 2025

The Market Herald

PYC Therapeutics Says Eye Disease Drug Candidate Dose Increase Approved by Safety Committee in Study; Shares Down 3%

MT Newswires Live

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

The Market Herald

ASX Market Update: Index rises on eve of Trump’s inauguration | January 20, 2025

The Market Herald

Why Australian Ethical, PYC, Resolute, and Star shares are falling today

PYC Therapeutics Says US FDA Grants Rare Pediatric Disease Designation to Eye Disease Drug Candidate; Shares Down 4%

MT Newswires Live

BRIEF-PYC Therapeutics Says U.S. FDA Grants Rare Pediatric Disease Designation To VP-001

PYC Therapeutics Ltd - U.S. FDA Grants Rare Pediatric Disease Designation to Vp-001

THOMSON REUTERS

Individual investors are PYC Therapeutics Limited's (ASX:PYC) biggest owners and were hit after market cap dropped AU$68m

Simply Wall St.

PYC Therapeutics Limited's (ASX:PYC) top owners are individual investors with 48% stake, while 42% is held by insiders

Simply Wall St.

PYC Therapeutics Chooses Fourth Drug Candidate for Genetic Disease Program; Shares Tumble 6%

MT Newswires Live

2 ASX healthcare small-cap shares to buy now: brokers

8 ASX All Ords shares upgraded to 'strong buy' ratings in November

18 stocks backed by a fund that returned 42% in 12 months

PYC Therapeutics Ltd-Update - Consolidation/Split - Pyc

THOMSON REUTERS

ASX Market Close: RBA keeps rates on hold amid sticky inflation | November 5, 2024

The Market Herald

PYC Therapeutics Says Safety Review Committee Approves Dose Escalation to Final Patient Group in Eye Disease Study; Shares Down 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PYC.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PYC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","market":"AU","secType":"STK","nameCN":"PYC THERAPEUTICS LTD","latestPrice":1.24,"timestamp":1746079920000,"preClose":1.175,"halted":0,"volume":513068,"delay":0,"nameEN":"PYC THERAPEUTICS LTD","floatShares":315767380,"shares":583260447,"eps":-0.110129,"marketStatus":"Closed","change":0.065,"latestTime":"05-01 16:12:00 AEST","open":1.2,"high":1.24,"low":1.17,"amount":615046,"amplitude":0.059574,"askPrice":1.24,"askSize":23440,"bidPrice":1.21,"bidSize":26000,"shortable":3,"etf":0,"ttmEps":-0.110129,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746144000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":1.175,"openAndCloseTimeList":[[1746057600000,1746079200000]],"volumeRatio":2.148839,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PYC.AU\",,,,,undefined,":{"symbol":"PYC.AU","floatShares":315767380,"roa":"-58.01%","roe":"-112.79%","lyrEps":-0.095849,"volumeRatio":2.148839,"shares":583260447,"dividePrice":0,"high":1.24,"amplitude":0.059574,"preClose":1.175,"low":1.17,"week52Low":0.9,"pbRate":"13.05","psRate":"28.94","week52High":2.1,"institutionHeld":0,"latestPrice":1.24,"committee":0.05178,"eps":-0.110129,"divideRate":0,"volume":513068,"delay":0,"ttmEps":-0.110129,"open":1.2,"prevYearClose":1.32,"prevWeekClose":1.115,"prevMonthClose":1.175,"prevQuarterClose":1.22,"fiveDayClose":1.03,"twentyDayClose":1.22,"sixtyDayClose":1.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PYC.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510507442","title":"BUZZ-Australia's PYC Therapeutics climbs to 1-month high on approval for human trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2510507442","media":"Reuters","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510507442?lang=en_us&edition=fundamental","pubTime":"2025-02-10 09:25","pubTimestamp":1739150732,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's PYC Therapeutics climbs to 1-month high on approval for human trials ** Shares of PYC Therapeutics PYC.AX rise as much as 4.8% to A$1.313, their highest levels since January 8** The biotechnology co says it has received regulatory approval to start human trials of its drug candidate, which addresses an underlying cause of Polycystic Kidney Disease ** PKD is a genetic disorder that causes the growth of numerous cysts in the kidneys** Stock has fallen 1.5% YTD, including current session's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL4N3P1030:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2510607604","title":"PYC Therapeutics Gets Regulatory Approval to Start Human Trials for Polycystic Kidney Disease Drug Candidate; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510607604","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510607604?lang=en_us&edition=fundamental","pubTime":"2025-02-10 08:25","pubTimestamp":1739147123,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  received all regulatory approvals to start human trials of its drug candidate for polycystic kidney disease, the company said in a Monday Australian bourse filing.Polycystic kidney disease is a life-changing disease where multiple cysts form throughout a patient's kidney that increase in size over time.Dosing of patients in the single ascending dose study is expected to be completed in about 12 months with a budgeted cost of AU$10 million, per the filing. The primary endpoint is treatment-emergent adverse events and treatment-emergent serious adverse events.The initial human safety and efficacy data are anticipated within the year, the filing added.Company shares were up nearly 3% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7067","PYC.AU","LENZ"],"gpt_icon":0},{"id":"2509789950","title":"PYC Therapeutics' (ASX:PYC) investors will be pleased with their splendid 107% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2509789950","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509789950?lang=en_us&edition=fundamental","pubTime":"2025-02-07 04:35","pubTimestamp":1738874144,"startTime":"0","endTime":"0","summary":"The last three months have been tough on PYC Therapeutics Limited  shareholders, who have seen the share price decline a rather worrying 36%. But that doesn't change the fact that the returns over the last five years have been very strong. It's fair to say most would be happy with 103% the gain in that time. To some, the recent pullback wouldn't be surprising after such a fast rise. The more important question is whether the stock is too cheap or too expensive today.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.Check out our latest analysis for PYC Therapeutics. It's good to see that PYC Therapeutics has rewarded shareholders with a total shareholder return of 60% in the last twelve months. That gain is better than the annual TSR over five years, which is 16%. Therefore it seems li","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pyc-therapeutics-asx-pyc-investors-203544149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PYC.AU","BK7067","BK4139","LENZ"],"gpt_icon":0},{"id":"2507818549","title":"ASX Market Update: Real Estate & mining stocks lead index to another all-time high | January 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507818549","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507818549?lang=en_us&edition=fundamental","pubTime":"2025-01-31 10:56","pubTimestamp":1738292160,"startTime":"0","endTime":"0","summary":"The ASX200 has hit yet another all-time high of 8,566 points in morning trade.The record was driven by a strong lead from Wall Street as well as buoyant mining and real estate stocks.Real Estate was the best performing sector, up 1.3%, followed by Materials, up 1.1%, and IT, up 0.85%. Utilities was the poorest performer, down 2.8%, followed by Telecommunication, down 0.25%.Mesoblast  has been up 2.3% on news of the U.S. launch of Ryoncil for pediatric graft-versus-host disease. The company says the focus is on finalising logistics and approvals to make the product available this quarter.Origin Energyhas been down 4.6% after revising its 2025 LNG production forecast. The company’s LNG revenue for the December 2024 quarter rose 3% from the previous quarter, reaching $2.71 billion, driven by higher LNG volumes and prices.PYC Therapeutics has been down 1.2% after to the next stage of its escalating single-dose study using its drug to treat a genetic children’s disease causing blindness.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-real-estate-mining-stocks-lead-index-to-another-all-time-high-january-31-2025-2025-01-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["MSB.AU","BK7507","BK7501","BK7067","BK7508","BK7130","PYC.AU","BK7006","ORG.AU"],"gpt_icon":0},{"id":"2507983074","title":"PYC Therapeutics Says Eye Disease Drug Candidate Dose Increase Approved by Safety Committee in Study; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507983074","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507983074?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:46","pubTimestamp":1738287984,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said a safety review committee approved an increase in dosage for its eye disease drug candidate in a single ascending dose study, according to a Friday filing with the Australian bourse.The committee monitoring the study approved an increase in the PYC-001 treatment dose from 3 micrograms per eye to 10 micrograms per eye following evaluation of data for patients in the first group through four weeks of follow-up.PYC-001 is a drug candidate for a childhood eye disease, autosomal dominant optic atrophy. The firm noted that there are currently no treatment options available for the disease.It will progress to dosing patients in the second group of the study to establish the safety and initial efficacy profile of the drug candidate.Its shares fell nearly 3% in recent trading on Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","BK4139","PYC.AU"],"gpt_icon":0},{"id":"2507898689","title":"PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit","url":"https://stock-news.laohu8.com/highlight/detail?id=2507898689","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507898689?lang=en_us&edition=fundamental","pubTime":"2025-01-31 07:47","pubTimestamp":1738280820,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.Autosomal Dominant Optic Atrophy  ultimately leads to lesions and leakage of fluids within the eye that deteriorates such that most with the condition are legally blind by middle age.After a review of the first batch of four-week data, the company has the green tick to continue. That would be normal in itself were it not for PYC’s +40% 1Y returns, putting it among a cohort of ASX biotech stocks currently having a fairly good run.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/pyc-therapeutics-jumps-just-shy-of-4-as-second-stage-blindness-drug-study-greenlit-2025-01-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["PYC.AU","BK7067","BK4139","LENZ"],"gpt_icon":0},{"id":"2504044661","title":"ASX Market Update: Index rises on eve of Trump’s inauguration | January 20, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2504044661","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504044661?lang=en_us&edition=fundamental","pubTime":"2025-01-20 10:40","pubTimestamp":1737340800,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.23% at 8,330 points.Donald Trump will be sworn in as the 47th President of the United States tomorrow Australian time, and investors are hyper alert to any potential surprises from the new President.Utilities has been the best performing sector, up 0.5%, followed by Discretionary and IT, both up 0.45%, and Financials, up 0.4%.The biggest gainer has beenTabcorp ,up 6.6% this afternoon; extending a 13.3% gain last week.Ioneer  has been up 20.6% after the company received a $1.6 billion loan from the US Department of Energy – in what is a record for an Australian company. The loan will be used to develop an on-site processing facility at the company’s Rhyolite Ridge lithium-boron project in Nevada.PYC Therapeutics  has been down 4.3% after the US Food and Drug Administration  granted it a Rare Pediatric Disease  designation for its drug development program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-rises-on-eve-of-trumps-inauguration-january-20-2025-2025-01-20/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7078","XAO.AU","BK7067","TAH.AU","INR.AU","LU1878469433.USD","RPD","XKO.AU","XJO.AU","BK4097","BK7504","BK7095","PYC.AU"],"gpt_icon":0},{"id":"2504456410","title":"Why Australian Ethical, PYC, Resolute, and Star shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2504456410","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504456410?lang=en_us&edition=fundamental","pubTime":"2025-01-20 09:11","pubTimestamp":1737335484,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher on Monday. In afternoon trade, the benchmark index is up 0.4% to 8,345.1 points. Four ASX shares that have failed to follow the marke","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/20/why-australian-ethical-pyc-resolute-and-star-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7104","PYC.AU","XAO.AU","BK7062","RSG.AU","BK7067","SGR.AU","AEF.AU","XJO.AU","BK7078","LU1878469433.USD","RPD","BK4097","XKO.AU","BK7506"],"gpt_icon":0},{"id":"2504198014","title":"PYC Therapeutics Says US FDA Grants Rare Pediatric Disease Designation to Eye Disease Drug Candidate; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504198014","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504198014?lang=en_us&edition=fundamental","pubTime":"2025-01-20 08:10","pubTimestamp":1737331837,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said the US Food and Drug Administration has granted Rare Pediatric Disease  designation to its drug candidate VP-001 for treating retinitis pigmentosa type 11, a blinding childhood eye disease, according to a Monday filing with the Australian bourse.Currently in phase 1/2 studies, VP-001 is set to enter a potentially registrational trial in 2025, the filing said.The RPD designation supports the development of therapies for serious, rare pediatric conditions, the filing added.Shares of the company fell almost 4% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1878469433.USD","RPD","BK4139","BK4097","PYC.AU","BK7067","LENZ"],"gpt_icon":0},{"id":"2504741602","title":"BRIEF-PYC Therapeutics Says U.S. FDA Grants Rare Pediatric Disease Designation To VP-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2504741602","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504741602?lang=en_us&edition=fundamental","pubTime":"2025-01-20 08:06","pubTimestamp":1737331603,"startTime":"0","endTime":"0","summary":"BRIEF-PYC Therapeutics Says U.S. FDA Grants Rare Pediatric Disease Designation To VP-001Jan 20 (Reuters) - PYC Therapeutics Ltd PYC.AX:U.S. FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO VP-001Further company coverage: PYC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OE06B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2504741843","title":"PYC Therapeutics Ltd - U.S. FDA Grants Rare Pediatric Disease Designation to Vp-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2504741843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504741843?lang=en_us&edition=fundamental","pubTime":"2025-01-20 06:36","pubTimestamp":1737326199,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250119:nFWN3OE06B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","PYC.AU"],"gpt_icon":0},{"id":"2503662696","title":"Individual investors are PYC Therapeutics Limited's (ASX:PYC) biggest owners and were hit after market cap dropped AU$68m","url":"https://stock-news.laohu8.com/highlight/detail?id=2503662696","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503662696?lang=en_us&edition=fundamental","pubTime":"2025-01-15 08:59","pubTimestamp":1736902780,"startTime":"0","endTime":"0","summary":"Key Insights PYC Therapeutics' significant individual investors ownership suggests that the key decisions are...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/individual-investors-are-pyc-therapeutics-limiteds-asxpyc-bi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PYC.AU","LENZ","BK4139","BK7067"],"gpt_icon":0},{"id":"2502020941","title":"PYC Therapeutics Limited's (ASX:PYC) top owners are individual investors with 48% stake, while 42% is held by insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2502020941","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502020941?lang=en_us&edition=fundamental","pubTime":"2025-01-10 05:26","pubTimestamp":1736457988,"startTime":"0","endTime":"0","summary":"The considerable ownership by individual investors in PYC Therapeutics indicates that they collectively have a greater say in management and business strategy. A total of 9 investors have a majority stake in the company with 50% ownership. Every investor in PYC Therapeutics Limited  should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 48% ownership. In other words, the group stands to gain the most  from their investment into the company.And individual insiders on the other hand have a 42% ownership in the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders.Let's delve deeper into each type of owner of PYC Therapeutics, beginning with the chart below.The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very leas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pyc-therapeutics-limiteds-asx-pyc-212628441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LENZ","PYC.AU","BK4139","BK7067"],"gpt_icon":0},{"id":"2491685202","title":"PYC Therapeutics Chooses Fourth Drug Candidate for Genetic Disease Program; Shares Tumble 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491685202","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491685202?lang=en_us&edition=fundamental","pubTime":"2024-12-16 09:33","pubTimestamp":1734312814,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  selected PYC-002 as the fourth drug candidate for its clinical trial program for Phelan-McDermid syndrome, a rare genetic disease characterized by a deficiency in a protein essential for neuron communication, according to a Monday filing with the Australian bourse.The company's pre-clinical studies showed that PYC-002 reaches the key areas of the brain affected by the disease in animal models and restores deficient protein expression to normal levels, the filing said.The company plans to advance PYC-002 into human trials, with first-in-human studies expected to start in the first half of 2026, the filing added.Shares of the company tumbled almost 6% in recent Monday trade.Price : $1.42, Change: $-0.09, Percent Change: -5.67%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0994945656.USD","AUD","BK4125","BK4139","LU2238339852.HKD","BK4121","PYC.AU","LU0426412945.USD","LU0345774631.USD","BK7067","LU0426417589.USD","GENE","LENZ","LU1043141123.HKD"],"gpt_icon":1},{"id":"2489492960","title":"2 ASX healthcare small-cap shares to buy now: brokers","url":"https://stock-news.laohu8.com/highlight/detail?id=2489492960","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489492960?lang=en_us&edition=fundamental","pubTime":"2024-12-06 03:00","pubTimestamp":1733425200,"startTime":"0","endTime":"0","summary":"ASX healthcare shares were in the red yesterday, with theS&P/ASX 200 Health Care Index(ASX: XHJ) down 0.21% while the broaderS&P/ASX All Ordinaries Index(ASX: XAO) was up 0.18%. Here are two ASX healt","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/06/2-asx-healthcare-small-cap-shares-to-buy-now-brokers/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7094","4DX.AU","BK7067","XAO.AU","PYC.AU"],"gpt_icon":0},{"id":"2488974857","title":"8 ASX All Ords shares upgraded to 'strong buy' ratings in November","url":"https://stock-news.laohu8.com/highlight/detail?id=2488974857","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488974857?lang=en_us&edition=fundamental","pubTime":"2024-12-04 05:37","pubTimestamp":1733261860,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords (ASX: XAO) shares soared 3.29% in November amid an early start to the traditional 'Santa Rally'.  AMP Ltd(ASX: AMP) Head of Investment Strategy and Economics, Dr Shane Oliver, said ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/04/8-asx-all-ords-shares-upgraded-to-strong-buy-ratings-in-november/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AMP.AU","BK7506","MAQ.AU","AAC.AU","XJO.AU","BK7141","BK7067","GOR.AU","BK7154","SMP.AU","XAO.AU","PYC.AU","BK7500","BK7095","BK7042","GQG.AU","BK7112","REIT.AU","BK7158","REIT","BK7505","BK7507","BK7033","BK7043","SYR.AU","BK7510","NST.AU","BK7122","BK7062","DEG.AU","DXS.AU","XKO.AU","BK7104"],"gpt_icon":1},{"id":"2484798937","title":"18 stocks backed by a fund that returned 42% in 12 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2484798937","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484798937?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:20","pubTimestamp":1731982807,"startTime":"0","endTime":"0","summary":"Small-cap stocks have experienced a renaissance over the last 12 months, with the Small Ordinaries Index returning 26.55% to the end of October. Investors have their sights on a continued small-cap recovery, as the economic storm clouds that have plagued the index finally appear to have cleared after several years of large-cap outperformance.According to consensus estimates, economists suggest that the recent slowdown bottomed in the second quarter of 2024. This is a good environment for active stockpickers, with the median small-cap manager outperforming in every economic recovery over the last 20 years (with an average return of 37% versus the ASX 100's 20% in these nine instances (see below).And yet, despite the stellar run in small-cap stocks over the last 12 months, the ASX Small Ordinaries Index remains cheap. That's according to Firetrail's small-cap team, who believe the index is currently offering up the \"cheapest growth in the world\".","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/18-stocks-backed-by-a-fund-that-returned-42-in-12-months","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/18-stocks-backed-by-a-fund-that-returned-42-in-12-months","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["NXG.AU","BK7113","FFM.AU","GMD.AU","BK7511","BK7067","HUB.AU","PMV.AU","BK7016","XKO.AU","A1M.AU","BK7062","IDX.AU","BK7096","BK7021","BK7508","QOR.AU","CAJ.AU","REG.AU","XJO.AU","360.AU","MYR.AU","PYC.AU","WHC.AU","BK7095","WC8.AU","BK7008","BK7507","XAO.AU","GDG.AU","AEL.AU","BK7041","WES.AU","NWL.AU","SFR.AU","BK7089","BK7110","BK7153","BLX.AU","BK7054","BK7104","BK7506","NEU.AU","BK7024","BK7083","BK7029","BK7124"],"gpt_icon":0},{"id":"2483501758","title":"PYC Therapeutics Ltd-Update - Consolidation/Split - Pyc","url":"https://stock-news.laohu8.com/highlight/detail?id=2483501758","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483501758?lang=en_us&edition=fundamental","pubTime":"2024-11-13 12:06","pubTimestamp":1731470809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUEDKGC9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYC.AU","BK7067"],"gpt_icon":0},{"id":"2481543313","title":"ASX Market Close: RBA keeps rates on hold amid sticky inflation | November 5, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481543313","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481543313?lang=en_us&edition=fundamental","pubTime":"2024-11-05 13:54","pubTimestamp":1730786040,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.4% at 8,131 points.The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced inflation is going to be back in the target band.All sectors lost ground and Utilities was the worst performer, down 0.7%, followed closely by Financials, down 0.6%, and Health Care and Staples, both down 0.55%.Peppermint Innovation closed flat on a new funding agreement to bolster its digital growth strategy and financial inclusion efforts in the Philippines. The company secured up to $3 million through convertible notes from Obsidian Global.Recce Pharmaceutical Ltd closed up 4.49% after reaching a milestone in its Phase II clinical trial to test the efficacy of its topical gel for treatment of Acute Bacterial Skin and Skin Structure Infections.Augustus Minerals  closed flat on news its acquiring a gold project in WA ripe for exploration and near several functioning mines.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-rba-keeps-rates-on-hold-amid-sticky-inflation-november-5-2024-2024-11-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7153","HVN.AU","PYC.AU","RCE.AU","AUG.AU","BK7509","BK7095","PDN.AU","BK7041","BK7067","PIL.AU","BK7083","BK7016","BK7096"],"gpt_icon":0},{"id":"2481596927","title":"PYC Therapeutics Says Safety Review Committee Approves Dose Escalation to Final Patient Group in Eye Disease Study; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481596927","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481596927?lang=en_us&edition=fundamental","pubTime":"2024-11-05 09:21","pubTimestamp":1730769684,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said the safety review committee governing its multiple dose studies in patients with retinitis pigmentosa type 11 approved escalation in dosing to the final patient group in the combined phase 1/2 studies of drug candidate VP-001, according to a Tuesday filing with the Australian bourse.Retinitis pigmentosa type 11 is a blinding eye disease affecting one in every 100,000 people, the filing said.Patients in the 75-microgram group of the multiple ascending dose  study can be enrolled in the trial and receive their first dose of VP-001 before the end of the month, according to the filing.The final patient group data from the MAD study, expected to be available in the first quarter of 2025, will aid in collaborating with the US Food and Drug Administration on the design of the registrational study to support a new drug application for VP-001.PYC Therapeutics shares fell nearly 3% in morning trade Tuesday.Price : $0.19, Change: $-0.01, Percent Change: -2.63%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","LU0994945656.USD","BK7067","AUD","LU1043141123.HKD","PYC.AU","BK7064","LU0426412945.USD","LU0345774631.USD","LENZ","LU0426417589.USD","BK4139","LU2238339852.HKD","MAD.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PYC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-11-15","symbol":"PYC.AU","defaultRemindTime":1731625200000,"type":"split","dateTimestamp":1731589200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"AU","date":"2024-03-18","symbol":"PYC.AU","defaultRemindTime":1710716400000,"type":"split","dateTimestamp":1710680400000,"forFactor":988235,"toFactor":1000000,"ratio":0.988235}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PYC.AU\",market:\"AU\",,,undefined,":[]}}